Moxifloxacin
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Antibiotics | Moxifloxacin | 400mg IV/PO Q24H | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 401 | 19-22 | 12-15 | 14.5-16 | 45-50 | 1.7-3.5 | N/A | N/A |
References:
- Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
- Czock D, Hüsig-Linde C, Langhoff A et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clinical journal of the American Society of Nephrology (CJASN) 2006; 1(6), 1263-8.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00218
- Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. The Journal of antimicrobial chemotherapy 2004; 54(4), 780-4.
- Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
- Launay-Vacher V, Izzedine H, Deray G. Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure. Clinical pharmacokinetics 2005; 44(3), 221-35.
- Stass H, Bührmann S, Mitchell A et al. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction. British journal of clinical pharmacology 2007; 64(6), 745-9.